首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   171638篇
  免费   13232篇
  国内免费   6429篇
耳鼻咽喉   1088篇
儿科学   4465篇
妇产科学   2089篇
基础医学   29891篇
口腔科学   2080篇
临床医学   11861篇
内科学   35392篇
皮肤病学   2843篇
神经病学   11208篇
特种医学   3099篇
外国民族医学   28篇
外科学   12659篇
综合类   18787篇
现状与发展   33篇
一般理论   2篇
预防医学   15812篇
眼科学   2012篇
药学   21263篇
  30篇
中国医学   6030篇
肿瘤学   10627篇
  2023年   2629篇
  2022年   5849篇
  2021年   6668篇
  2020年   5595篇
  2019年   7014篇
  2018年   6744篇
  2017年   5838篇
  2016年   5674篇
  2015年   6401篇
  2014年   9389篇
  2013年   10409篇
  2012年   9230篇
  2011年   10964篇
  2010年   9119篇
  2009年   7932篇
  2008年   7684篇
  2007年   7420篇
  2006年   6478篇
  2005年   5793篇
  2004年   5151篇
  2003年   4484篇
  2002年   3627篇
  2001年   3360篇
  2000年   2739篇
  1999年   2543篇
  1998年   2131篇
  1997年   2086篇
  1996年   1744篇
  1995年   1636篇
  1994年   1460篇
  1993年   1240篇
  1992年   1016篇
  1991年   940篇
  1990年   827篇
  1989年   702篇
  1988年   664篇
  1987年   529篇
  1985年   1795篇
  1984年   2174篇
  1983年   1636篇
  1982年   1777篇
  1981年   1658篇
  1980年   1398篇
  1979年   1299篇
  1978年   1000篇
  1977年   814篇
  1976年   998篇
  1975年   792篇
  1974年   661篇
  1973年   606篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
A 42‐year‐old man presented with a viral prodrome and tested positive for influenza A. He rapidly deteriorated developing cardiogenic shock, rhabdomyolysis, and acute kidney injury. Patient improved 1 week later with supportive measures including vasopressors, inotropes, and an intraaortic balloon pump. We report this case as it highlights the discordance between echocardiographic ventricular wall thickening as a result of myocardial edema, and electrocardiographic findings at presentation, with a reversal in findings at time of resolution. Additionally, there was some suggestion of a regional pattern to the reduced longitudinal strain.  相似文献   
3.
1. To investigate Genkwa Flos hepatotoxicity, a cell metabolomics strategy combined with serum pharmacology was performed on human HL-7702 liver cells in this study.

2. Firstly, cell viability and biochemical indicators were determined and the cell morphology was observed to confirm the cell injury and develop a cell hepatotoxicity model. Then, with the help of cell metabolomics based on UPLC-MS, the Genkwa Flos group samples were completely separated from the blank group samples in the score plots and seven upregulated as well as two down-regulated putative biomarkers in the loading plot were identified and confirmed. Besides, two signal molecules and four enzymes involved in biosynthesis pathway of lysophosphatidylcholine and the sphingosine kinase/sphingosine-1-phosphate pathway were determined to investigate the relationship between Genkwa Flos hepatotoxicity and these two classic pathways. Finally, the metabolic pathways related to specific biomarkers and two classic metabolic pathways were analyzed to explain the possible mechanism of Genkwa Flos hepatotoxicity.

3. Based on the results, lipid peroxidation and oxidative stress, phospholipase A2/lysophosphatidylcholine pathway, the disturbance of sphingosine-1-phosphate metabolic profile centered on sphingosine kinase/sphingosine-1-phosphate pathway and fatty acid metabolism might be critical participators in the progression of liver injury induced by Genkwa Flos.  相似文献   

4.
5.
Introduction: Major Depressive Disorder (MDD) and General Anxiety Disorder (GAD) significantly contribute to the global burden of disease. Vilazodone, a combined serotonin reuptake inhibitor and 5-HT1A partial agonist, is an approved therapy for the treatment of MDD and which has been further investigated for GAD.

Areas covered: This article covers the pharmacokinetics and pharmacodynamics of vilazodone and provides an evaluation of the clinical usefulness of vilazodone for the treatment of MDD and anxiety disorders. A literature search was performed using PubMed/MEDLINE, Web of Science and the Cochrane Library.

Expert opinion: Studies have shown that vilazodone is significantly superior to placebo. However, vilazodone cannot as yet be recommended as a first-line treatment option for MDD as it is unclear whether the drug’s dual mechanism of action provides greater efficacy than prevailing treatment options. Moreover, more phase IV studies are needed to establish its efficacy and long-term safety in larger and more diverse populations. Although vilazodone may have an additional advantage for the treatment of anxiety symptoms in MDD, here also additional studies are required to confirm its efficacy over and above SSRI alternatives and other antidepressant treatments. Therefore, presently, vilazodone should be considered as a second- or third-line treatment option for MDD and GAD.  相似文献   

6.
7.
8.
9.
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号